Delivery Order SPE2DB24D1205-SPE2DB25FCVLP
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,373.84 to AmerisourceBergen Drug Corp for Risperdal 0.5 mg tablets (60-count units) with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.16 to AmerisourceBergen Drug Corp for the supply of Risperdal (risperidone) 2 mg tablets in a 60-count package. This competitively awarded, non-set-aside firm fixed price delivery order was issued on September 5, 2025, with an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency awarded a $12,175.63 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Risperdal 2 mg tablets in quantities of 60 units. This competitively awarded, firm fixed-price contract includes performance through September 11, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,054.47 to AmerisourceBergen Drug Corp for the supply of Risperidone 2 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on April 24, 2025, with an ultimate completion date of April 25, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Risperdal 2 mg tablets in quantities of 60 units, with a ceiling value of $2,008.32. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order...
- The Defense Logistics Agency's Medical Supply Chain awarded a $2,130.74 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Risperdal 0.5 mg on September 19, 2025, with a completion date of September 22, 2025. This competitively awarded, non-set-aside contract reflects a firm fixed-price delivery order structure typical of the agency's pharmaceutical procurement operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,897.50 to AmerisourceBergen Drug Corp for the supply of Risperdal 0.5 mg tablets (60-count units) under a firm fixed price contract. The delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Risperdal 0.5 mg tablets (60-count packages) with a contract value of $1,130.40. This is a firm fixed-price delivery order with an ultimate completion date of July 24, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation and represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Risperidone 2 mg tablets in quantities of 60 units at a firm fixed price of $2,213.75. The contract carries an ultimate completion date of July 17, 2025, and represents a non-set-aside, competitively awarded procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a $1,387.02 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Risperdal 2 mg, a pharmaceutical product used in treating psychiatric conditions. This firm fixed-price delivery order, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation, indicating it was competitively awarded...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCVLPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Risperdal (risperidone) 2 mg tablets in a 60-count configuration, valued at $1,396.10. This non-set-aside contract was competitively awarded on April 1, 2025, with an ultimate completion date of April 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes firm fixed price terms under a delivery order structure. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a broad portfolio of medications and medical supplies to support military healthcare programs, the Defense Health Agency, and other government healthcare systems worldwide. The company's federal procurement activities demonstrate consistent capability to deliver pharmaceutical products across multiple therapeutic domains through competitively awarded contracts with flexible delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 4/1/25 |